Sangamo Therapeutics IncAfter Sangamo Therapeutics Inc. presented an epigenetic ZFN-based repressor at ASGCT 2024 that reduces the expression of the tau protein in the hippocampus by 95% in Alzheimer’s models, Roche’s US subsidiary Genentech has licensed the experimental gene therapy.
Tag Archive for: Alzheimer’s
AC Immune SASwiss AC Immune and its partner Janssen Pharmaceuticals Inc have been granted FDA Fast Track Designation for their active anti-pTau vaccine ACI-35.030/JNJ-2056 to treat Alzheimer’s disease.
AC Immune and Takeda have inked an exclusive option license agreement for ACI-24.060, a first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression.
ALS specialist NeuroSense Therapeutics Ltd announces it will be collaborating with Swiss Lonza AG to identify exosome-based biomarkers to advance theranostics in neurodegeneration.
Genentech, Roches US subsidiary, is ending its decades-long collaboration with AC Immune SA after disappointing study results. It has handed the global rights to Crenezumab and Semorinemab back to the Lausanne-based biotech.
Alzheimers specialist AstronauTx Ltd has closed a £48m Series A financing to create new treatments for Alzheimers diseas
A Belgian-British research team has identified the human protein underlying necroptosis of human brain cells in Alzheimer’s mice and stopped cell death.
Eli Lilly’s Alzheimer’s drug donanemab has speedy removed amyloid plaques in a pivotal Phase III trail halting disease progression for one year in half of patients.
German Neotiv GmbH hat closed a €10m seed financing to speed-up product launch of its early diagnosis app for Alzheimer’s disease